The median progression-free survival (PFS) was significantly improved with atezolizumab plus nab-paclitaxel compared to placebo plus nab-paclitaxel (7.5 months (95%CI 6.7–9.2) vs. 5.0 months (95%CI 3.8–5.6); hazard ratio [HR] 0.62, 95% CI 0.49–0.78; p < 0.0001) in the PD-L1 immune-cell positive subgroup (tumors that express PD-L1 on immune cells that cover 1% or more of the tumor area). Here, CD274 is linked to neoplasm.